Izotropic Prepares New Platforms to Educate and Engage
Izotropic (OTCQB: IZOZF) has announced strategic awareness initiatives ahead of the commercialization of its IzoView Breast CT Imaging System. The company is launching three key platforms: a comprehensive awareness campaign, a new podcast series, and a dedicated website at breastct.com.
The awareness campaign will focus on highlighting IzoView's proprietary features, including patented hardware innovations, trade-secret software elements, and next-generation AI integrations. The podcast series will provide commentary on corporate updates, clinical milestones, and regulatory progress. The breastct.com website will serve as an educational resource for patients, clinicians, and advocates regarding breast CT technology.
Izotropic (OTCQB: IZOZF) ha annunciato iniziative strategiche di sensibilizzazione in vista della commercializzazione del suo Sistema di Imaging Mammario CT IzoView. L'azienda lancerà tre piattaforme principali: una campagna di sensibilizzazione completa, una nuova serie di podcast e un sito web dedicato all'indirizzo breastct.com.
La campagna di sensibilizzazione si concentrerà sull'evidenziare le caratteristiche proprietarie di IzoView, tra cui innovazioni hardware brevettate, componenti software segreti e integrazioni AI di nuova generazione. La serie di podcast offrirà commenti su aggiornamenti aziendali, traguardi clinici e progressi normativi. Il sito breastct.com fungerà da risorsa educativa per pazienti, medici e sostenitori riguardo alla tecnologia CT mammaria.
Izotropic (OTCQB: IZOZF) ha anunciado iniciativas estratégicas de concienciación antes de la comercialización de su Sistema de Imagen por Tomografía Computarizada Mamaria IzoView. La empresa lanzará tres plataformas clave: una campaña integral de concienciación, una nueva serie de podcasts y un sitio web dedicado en breastct.com.
La campaña de concienciación se centrará en destacar las características propias de IzoView, incluyendo innovaciones de hardware patentadas, elementos de software confidenciales e integraciones de IA de próxima generación. La serie de podcasts proporcionará comentarios sobre actualizaciones corporativas, hitos clínicos y avances regulatorios. El sitio web breastct.com servirá como un recurso educativo para pacientes, clínicos y defensores sobre la tecnología de tomografía computarizada mamaria.
Izotropic (OTCQB: IZOZF)는 IzoView 유방 CT 영상 시스템 상용화를 앞두고 전략적 인식 제고 활동을 발표했습니다. 회사는 포괄적인 인식 캠페인, 새로운 팟캐스트 시리즈, breastct.com에 전용 웹사이트 등 세 가지 주요 플랫폼을 출시할 예정입니다.
인식 캠페인은 특허받은 하드웨어 혁신, 영업 비밀 소프트웨어 요소, 차세대 AI 통합 등 IzoView의 독자적 기능을 강조하는 데 중점을 둘 것입니다. 팟캐스트 시리즈는 회사 소식, 임상 성과, 규제 진행 상황에 대한 해설을 제공할 것입니다. breastct.com 웹사이트는 환자, 임상가, 옹호자를 위한 유방 CT 기술 교육 자료로 활용됩니다.
Izotropic (OTCQB : IZOZF) a annoncé des initiatives stratégiques de sensibilisation en vue de la commercialisation de son Système d’Imagerie TDM mammaire IzoView. L’entreprise lance trois plateformes clés : une campagne de sensibilisation complète, une nouvelle série de podcasts et un site web dédié à breastct.com.
La campagne de sensibilisation mettra en avant les caractéristiques exclusives d’IzoView, notamment des innovations matérielles brevetées, des éléments logiciels confidentiels et des intégrations d’IA de nouvelle génération. La série de podcasts proposera des commentaires sur les mises à jour de l’entreprise, les avancées cliniques et les progrès réglementaires. Le site breastct.com servira de ressource éducative pour les patientes, les cliniciens et les défenseurs de la technologie TDM mammaire.
Izotropic (OTCQB: IZOZF) hat strategische Aufklärungsinitiativen im Vorfeld der Kommerzialisierung seines IzoView Brust-CT-Bildgebungssystems angekündigt. Das Unternehmen startet drei zentrale Plattformen: eine umfassende Aufklärungskampagne, eine neue Podcast-Serie und eine dedizierte Webseite unter breastct.com.
Die Aufklärungskampagne wird sich darauf konzentrieren, die proprietären Merkmale von IzoView hervorzuheben, darunter patentierte Hardware-Innovationen, geschützte Softwareelemente und KI-Integrationen der nächsten Generation. Die Podcast-Serie bietet Kommentare zu Unternehmensneuigkeiten, klinischen Meilensteinen und regulatorischen Fortschritten. Die Webseite breastct.com wird als Bildungsressource für Patienten, Kliniker und Befürworter der Brust-CT-Technologie dienen.
- Development of three new communication platforms to enhance market presence
- Strategic positioning of IzoView's proprietary technology features
- Creation of dedicated educational resources for stakeholders
- Product not yet commercialized or approved by regulators
- No immediate revenue generation from these initiatives
- Strategic awareness initiatives underway ahead of IzoView commercialization -
- Company podcast and breasct.com website in development to expand engagement -
- Market-facing activities aligned with investor communications and corporate milestones -
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - July 15, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it is initiating strategic awareness plans in anticipation of the future commercialization of its breakthrough device, the IzoView Breast CT Imaging System.
Izotropic's awareness efforts will center on a consistent and compelling stream of development-related news to educate global audiences on the transformative value of dedicated breast CT technology. These initiatives will spotlight how IzoView stands apart from traditional breast imaging modalities and competing breast CT systems, positioning it as a true game-changer in the field. The campaign will emphasize IzoView's unique, proprietary features including patented hardware innovations, trade-secret software elements, and next-generation AI integrations, to reinforce the device's competitive edge and accelerate market adoption. Emerging breast imaging trends, evolving regulatory frameworks, and robust market growth forecasts will be incorporated to contextualize IzoView's potential. The Company's narrative will be refined, data-driven, and strategically repackaged to engage new audiences and support its commercialization and go-to-market initiatives.
To complement these efforts and broaden reach while building on a growing stream of corporate developments, Izotropic will launch a new podcast series focused on discussing Company news and key milestones as they unfold. The podcast will deliver clear and timely commentary on Izotropic's corporate updates, providing context around press releases, clinical milestones, regulatory progress, and strategic initiatives, while highlighting relevant developments across the breast imaging and medical technology sectors to help listeners stay current on the trends shaping the commercial landscape. Designed to be concise and informative, the podcast will serve as a consistent communication channel for stakeholders, offering accessible insights as the Company advances toward market launch.
Supporting both the awareness campaign and podcast series, Izotropic will also introduce breastct.com. This dedicated online platform will initially feature articles about breast CT technology, the Company's progress, and the unique advantages of IzoView. The site is developed to evolve over time into a comprehensive educational resource, supporting patient awareness and engagement as Izotropic moves through regulatory processes in the U.S. and Europe. Overtime, breastct.com will serve as a centralized destination for patients, clinicians, and advocates seeking accessible, trusted information about IzoView and the evolving role of breast CT in cancer detection and care.
These efforts form part of a broader, coordinated awareness strategy developed in collaboration with Izotropic's capital markets and industry advisory team, with a focus on aligning investor engagement, investor communications, and market-facing activities with its long-term regulatory and commercialization objectives.
About Izotropic:
More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR+ at sedarplus.ca.
Forward-Looking Statements:
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all Forward-Looking Statements contain these identifying words.
These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.
Contacts:
Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast@izocorp.com
James Gagnon, International Communications
Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2
General and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/258830
FAQ
What new initiatives did Izotropic (IZOZF) announce for IzoView commercialization?
What are the key features of Izotropic's IzoView Breast CT Imaging System?
What is the purpose of Izotropic's new breastct.com website?
How will Izotropic's new podcast series benefit investors?
